We retrospectively contrasted the medical outcome of patients removed from the heart transplant consideration list because of clinical Improvement with that of transplant recipients.
Of 60 patients awaiting transplantation, 18 were removed from the list (group A), and 42 required transplant or died (group B).
Group A significantly Improved regarding exercise oxygen uptake, ejection fraction, and hemodynamics.
For more than 2 years after transplantation or « delisting, » both groups had comparable symptoms (New York Heart Association class I to II) and cardiovascular mortality (1 of 18 for group A vs 3 of 32 for group B) but lower hospitalizations for group A (0.5 ± 0.6 of 27 months per patient) versus group B (2.8 ± 2.1 of 23 months per patient) (p=0.0002).
Despite two patients who had been removed from the list requiring transplantation, savings for delisting exceeded $2.2 million.
Thus medical therapy allows transplant recipient list removal with clinical Improvements sustained for 1 to 3 years at significant cost savings.
Mots-clés Pascal : Insuffisance cardiaque, Homotransplantation, Coeur, Chimiothérapie, Economie santé, Coût, Traitement, Homme, Appareil circulatoire pathologie, Cardiopathie, Transplantation, Chirurgie
Mots-clés Pascal anglais : Heart failure, Homotransplantation, Heart, Chemotherapy, Health economy, Costs, Treatment, Human, Cardiovascular disease, Heart disease, Transplantation, Surgery
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0075549
Code Inist : 002B12A01. Création : 21/05/1997.